Immobilizing A Moving Target: CAR T Cells Hit CD22.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

A key mechanism of resistance to chimeric antigen receptor-modified T cells (CAR-T) is loss or downregulation of target antigens. Low antigen expression on cancer cells prevents full CAR-T-cell activation and persistence. Pharmacologic modulation of target antigen expression offers a novel therapeutic strategy to drive more potent and durable responses.See related article by Ramakrishna et al., p. 5329.

Keyphrases

poor prognosis
cell proliferation
signaling pathway
mouse model
immune response